JAK/TYK2
Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
Dr. John Cush RheumNow
1 year 7 months ago
Watch: Another TYK2 Ticks the Boxes
Dr. Janet Pope discusses late-breaking abstract L12 presented at #ACR23.
https://t.co/1SGuIFOWt6 https://t.co/tb4LRbmfiI
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.
Dr. Antoni Chan
1 year 7 months ago
JAKi, especially BARI, may be useful and safe in controlling both pulmonary and joint disease in RA-ILD patients, even in refractory cases. Evolution of FVC and DLCO remained stable in first 12 months. Serrano-Combarro A, Abst#2174 #ACR23 @RheumNow https://t.co/82mMn5oh15 https://t.co/e7wrgmTOTA
Richard Conway
1 year 7 months ago
Serrano-Combarro et al. JAKi in RA-ILD. 73 patients on JAKi (74% Bari). Many had prev received abatacept/rituximab. HRCT improved/stable in 76%. Dyspnoea stable/improved in 95%. Abstr#2174 #ACR23 @RheumNow https://t.co/j6SiEzSRif
Richard Conway
1 year 7 months ago
Long-term abatacept in UIP RA-ILD. 233 patients, median 22 month follow-up. Sustained benefits to previous data. ABA was withdrawn in 50 patients (21.5%) (ILD worsening 20, joint worsening 15, serious infections 7, others 8) Abstr#2165 #ACR23 @RheumNow https://t.co/SinE4GgFRE https://t.co/M1Nnce58OE
Dr. John Cush RheumNow
1 year 7 months ago
Who gives a ‘JAK’ why and how they work, as long as they do!
Several abstracts have studied the mechanism of action of JAKi in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. #ACR23
https://t.co/xqQF8SULgp https://t.co/DZtEly8GEq
sheila
1 year 7 months ago
In this Ph2b RCT of TAK-279 (TYK2i), pts w/ PsA given 15mg & 30mg achieved an ACR20 response at wk 12 vs. PBO(53.3% and 54.2% vs 29.2%, both p = 0.002)
⬆️common TEAEs: Npharyngitis, URTI, headache & rash
#ACR23 ABSL12 @RheumNow https://t.co/T6swJgw6vE
Mithu Maheswaranathan, MD
1 year 7 months ago
Clinical Year in Review at #ACR23
By @philseo (@jhrheumatology)
Review some of the most impactful scientific studies in #Rheumatology in the past year! 🍕 https://t.co/ystEjzrU8u
Robert B Chao, MD
1 year 7 months ago
Anterior uveitis incidence across different axSpA treatments
Large review and meta-analysis on TNFi, IL-17i, JAKi
Immunomodulatory therapy protective against uveitis flare
Greatest in TNFi and JAKi
@RheumNow #ACR23 Abs# 2550 https://t.co/l3BTL3GuRt
Poster Hall